Cochlear today announces the launch of the Nucleus® Profile™ Plus Series cochlear implant, designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet. Commercial availability commences in Germany with other European… Read More ›
Invion, which was formerly focused on the development of new drugs for respiratory disorders, in late 2017 changed direction with the acquisition of rights to a new Photodynamic Therapy (PDT) for the treatment of cancer. PDT, in which light-sensitive drugs… Read More ›
This article was originally published at MF & Co. Asset Management. Today we’ll show you why we think Volpara Health Technologies (ASX VHT) is a great stock to buy. In fact, this is a stock that we got our clients… Read More ›
Article written by Pitt Street Research. For the full report click here Following the gut The Anatara/Zoetis deal is a company maker Anatara Lifesciences, a Melbourne-based drug developer focusing on GI therapies, partnered with Zoetis in an exclusive worldwide licensing agreement… Read More ›
This article was originally published at MF & Co. Asset Management. Fisher & Paykel Healthcare (ASX FPH) designs, manufactures and markets medical devices and accessories for use in respiratory care, acute care, and the treatment of obstructive sleep apnoea. The… Read More ›
This article was originally published at MF & Co. Asset Management. Nanosonics (ASX NAN) has a clear and reliable strategy for future development and a revolutionary monopolistic product (Trophon 2). The company also just achieved regulatory approvals in key markets and… Read More ›
Article written by Pitt Street Research. For the full report click here Setting global benchmark in pain assessment PainChek is a Sydney-based pain assessment tool provider. Considering lack of any global benchmark in pain assessment, PainChek is expected to set a… Read More ›
Article written by Pitt Street Research. For the full report click here The Neuren/Acadia deal has been misunderstood When Neuren Pharmaceuticals, a drug development company focused on neurology drugs, partnered its lead molecule, called Trofinetide, to Acadia Pharmaceuticals in August 2018,… Read More ›
Article written by Pitt Street Research. For the full report click here NASDAQ listing would enable valuation comparison with true peers G Medical Innovations Holdings (ASX:GMV) is commercializing mobile vital signs monitoring systems that enable remote monitoring of patients. GMV’s products… Read More ›
This article was originally published at MF & Co. Asset Management. Medibank Private (ASX MPL) is an Australian-based private health insurance provider. Medibank is in the business of underwriting and distribution of private health insurance policies through Medibank and ahm brands…. Read More ›
So, how does one invest in a market that is due for a hard landing? Our strategy is spelled out in this article. I simply don’t trust the fundamentals of the global economy right now. The system is built on quicksand…. Read More ›
This article was originally published at MF & Co. Asset Management. Ramsay group (ASX RHC) is one of the top 5 private hospital operators in the world. Ramsay Health Care operates 235 hospitals, day surgery centres, treatment facilities, rehabilitation and… Read More ›
This article was originally published at MF & Co. Asset Management. Volpara Health Technologies Ltd (ASX VHT) is a New Zealand-based healthcare research, and development company with global scalability. The company provides medical software, specialising in managing the breast screening… Read More ›
This article is written by Vitaliy Katsenelson: contrarianedge.com Companies everywhere, in every business, are paranoid about Amazon.com. This sort of paranoia is healthy for the long-term well-being of our investment portfolio, as it is creating interesting buying opportunities. A case… Read More ›
Podcast produced by Jeremy Medlin. Jeremy reviews the stocks that are moving the NZX, ASX and international markets. Listen in each week for a new episode on Friday.In the third episode of the Stock Market Movers, Jeremy will go through the big… Read More ›
Article written by Pitt Street Research. For the full report click here Since the origin of CPAP in the early 1980s there have been treatment solutions for Obstructive Sleep Apnea, and these have created multi-billion-dollar companies such as ResMed. CPAP, however, while… Read More ›
Written by Vitaliy Katsenelson; contrarianedge.com Last week I explained why my firm is investing in pharmaceuticals stocks, despite the sector being a favorite punching bag of politicians. I noted that we have recently added to our existing positions in Amgen,… Read More ›
Article written by Pitt Street Research. For the full report click here G Medical Innovations Holdings Limited (ASX:GMV) is commercializing mobile vital signs monitoring systems that enable remote monitoring of patients. GMV’s products haveto potential to substantially lower healthcare costs and… Read More ›
This article was originally published at MF & Co. Asset Management. Mesoblast Limited (ASX MSB; Nasdaq MESO) is a Melbourne-based leading global stem cell company focusing on R&D in regenerative cellular medicines. The Mesoblast share price has been falling since… Read More ›
Article written by Pitt Street Research. For the full report click here Since the early 2000s Phosphagenics has spent more than A$100m on its drug reformulation technology called TPM®, built from Vitamin E. The company has ample pre-clinical and clinical data showing… Read More ›
This article was originally published at CoinCentral.com CSL Limited (ASX CSL) is a leading biotechnology company that researches, develops and markets across the global market. The business has a broad reach in the biotherapy industry with a differentiated product portfolio and commercial… Read More ›
Article written by Pitt Street Research. For the full report click here: Mobile monitoring of vital signs is the new Black G Medical Innovations Holdings (ASX:GMV) is an Israel-based company that is commercializing mobile vital signs monitoring systems that provide… Read More ›
This article was originally published at: MF & Co. Asset Management. Sonic Healthcare Limited (ASX SHL) is Australasia and Europe’s largest and the world’s third-largest medical laboratory provider. During the last financial year, Sonic Healthcare stock has been rewarded a… Read More ›
This article was originally published at MF & Co. Asset Management. With high-class medical research and health infrastructure, Australia’s health care system has been the global benchmark for decades. The Australian government invested about 3 billion Australian dollars per annum… Read More ›